A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.
创建时间：
2019-03-15
